Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset

Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact an early-stage assets out of small biotech Agenus. The headline hopeful is its preclinical TIGIT candidate, AGEN1777, currently in the later stages of preclinical development, with an IND for a clinical trial expected imminently. BMS also nabs rights to “a second undisclosed target” but gave no details on that.